LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266Phase 1 enrollment in LAVA-1266 clinical trial underwayJohnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024Cash balance of$76.6 million as of December 31, 2024 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, ...